Insights

Professional
Practice
Industry
Region
Trending Topics
Location
Type

Sort by:

Firm News 12 results

Firm News | 2 min read | 10.23.26

Three Crowell Lawyers Named to IAM Global Leaders 2027

Washington – October 23, 2026: Crowell & Moring’s Kristof Roox, Jan-Diederik Lindemans, and Justin Hill have been named to IAM Global Leaders 2027, which recognizes leading patent practitioners worldwide.  
...

Firm News | 4 min read | 07.22.26

Crowell & Moring Marks Six Months of Legora Integration with Transformative Results Across Global Platform

Washington, D.C. – July 22, 2026 – Crowell & Moring LLP today shared results from its firmwide integration of Legora as a collaborative AI platform. Crowell has realized significant gains in opportunities to deliver for clients across practices and jurisdictions.  
...

Firm News | 2 min read | 10.14.25

Crowell Earns Top Rankings from Legal 500 United Kingdom 2026

London – October 14, 2025: Crowell & Moring U.K. LLP has been recommended in five practice areas in the Legal 500 United Kingdom 2026.
...

Client Alerts 4 results

Client Alert | 6 min read | 09.28.26

AI-Assisted Drug Discovery After USPTO Inventorship Guidance Updates: Patentability, Conception, and Trade Secret Strategy

The rapid emergence of AI/ML tools in drug discovery, from target identification to generative molecular design, lead optimization, and repurposing, has transformed how life sciences companies build some of their most valuable assets. As AI/ML tools take on an increasingly significant role in the drug discovery process, companies face a set of largely unresolved IP challenges that require careful planning and proactive governance.  
...

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. 
...

Client Alert | 2 min read | 03.17.26

Qatar Introduces Licensing Framework for E-Commerce Activities Without a Physical Premises

On 4 March 2026, Qatar’s Ministry of Commerce and Industry (MoCI) issued Ministerial Decision No. (25) of 2026 (Decision), establishing a regulatory framework (Framework) for conducting commercial activities through electronic platforms that do not require a physical premises in Qatar. The Decision was published in the Official Gazette on 15 March 2026 and entered into force on 16 March 2026.
...

Press Coverage 8 results

Press Coverage | 09.24.26

What Will Europe’s Latest Greenwashing Regime Mean For Investors?

Europe Says (Syndicated from Responsible Investor)

Press Coverage | 09.23.26

Politico Playbook Transitions

POLITICO

Webinars 1 result

Webinar | 01.23.25, 4:00 PM CET - 7:00 PM CET

Trump Administration and What it Means for Businesses Outside the US

On 23 January 2025 at 16:00 CET, Crowell will host a webinar on the new Trump Administration and what it means for businesses outside the US. It will focus, in particular, on the Trump Administration’s policy objectives, how they will be implemented, and the legal and real-world impacts. By the date of the webinar, the new Trump Administration is expected to have issued its first Executive Orders, and there will be more clarity on their scope and content.